ID: ALA4087114

Max Phase: Preclinical

Molecular Formula: C27H23N3O8S2

Molecular Weight: 581.63

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccccc1NC(=O)c1c(NS(=O)(=O)c2ccc(C)cc2)cccc1S(=O)(=O)c1ccc([N+](=O)[O-])cc1

Standard InChI:  InChI=1S/C27H23N3O8S2/c1-18-10-14-21(15-11-18)40(36,37)29-23-7-5-9-25(39(34,35)20-16-12-19(13-17-20)30(32)33)26(23)27(31)28-22-6-3-4-8-24(22)38-2/h3-17,29H,1-2H3,(H,28,31)

Standard InChI Key:  QHEVDMPSKXIHJA-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 581.63

Molecular Weight (Monoisotopic): 581.0927

AlogP: 4.80

#Rotatable Bonds: 9

Polar Surface Area: 161.78

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 7.12

CX Basic pKa:

CX LogP: 4.80

CX LogD: 4.42

Aromatic Rings: 4

Heavy Atoms: 40

QED Weighted: 0.21

Np Likeness Score: -1.57

References

1. Zhou M, Luo RH, Hou XY, Wang RR, Yan GY, Chen H, Zhang RH, Shi JY, Zheng YT, Li R, Wei YQ..  (2017)  Synthesis, biological evaluation and molecular docking study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif antagonists.,  129  [PMID:28235704] [10.1016/j.ejmech.2017.01.010]

Source

Source(1):

• Scientific Literature